Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury

Jin Moo Lee, Ping Yan, Qingli Xiao, Shawei Chen, Kuang Yung Lee, Chung Y. Hsu, Jan Xu

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Methylprednisolone (MP) is used to treat a variety of neurological disorders involving white matter injury, including multiple sclerosis, acute disseminated encephalomyelitis, and spinal cord injury (SCI). Although its mechanism of action has been attributed to antiinflammatory or antioxidant properties, we examined the possibility that MP may have direct neuroprotective activities. Neurons and oligodendrocytes treated with AMPA or staurosporine died within 24 h after treatment. MP attenuated oligodendrocyte death in a dose-dependent manner; however, neurons were not rescued by the same doses of MP. This protective effect was reversed by the glucocorticoid receptor (GR) antagonist (11, 17)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl) estra-4,9-dien-3-one (RU486) and small interfering RNA directed against GR, suggesting a receptor-dependent mechanism. MP reversed AMPA-induced decreases in the expression of anti-apoptotic Bcl-xL, caspase-3 activation, and DNA laddering, suggesting anti-apoptotic activity in oligodendrocytes. To examine whether MP demonstrated this selective protection in vivo, neuronal and oligodendrocyte survival was assessed in rats subjected to spinal cord injury (SCI); groups of rats were treated with or without MP in the presence or absence of RU486. Eight days after SCI, MP significantly increased oligodendrocytes (CC-1-immunoreactive cells) after SCI, but neuronal (neuronal-specific nuclear protein-immunoreactive cells) number remained unchanged; RU486 reversed this protective effect. MP also inhibited SCI induced decreases in Bcl-xL and caspase-3 activation. Consistent with these findings, the volume of demyelination, assessed by Luxol fast blue staining, was attenuated by MP and reversed by RU486. These results suggest that MP selectively inhibits oligodendrocyte but not neuronal cell death via a receptor-mediated action and may be a mechanism for its limited protective effect after SCI.

Original languageEnglish
Pages (from-to)3141-3149
Number of pages9
JournalJournal of Neuroscience
Volume28
Issue number12
DOIs
Publication statusPublished - Mar 19 2008

Fingerprint

Oligodendroglia
Methylprednisolone
Spinal Cord Injuries
Neurons
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid
Glucocorticoid Receptors
Caspase 3
Acute Disseminated Encephalomyelitis
Staurosporine
Demyelinating Diseases
Nuclear Proteins
Nervous System Diseases
Small Interfering RNA
Multiple Sclerosis
Cell Death
Anti-Inflammatory Agents
Cell Count
Antioxidants
Staining and Labeling

Keywords

  • Apoptosis
  • Glucocorticoids
  • Methylprednisolone
  • Neurons
  • Oligodendrocytes
  • Spinal cord injury

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Lee, J. M., Yan, P., Xiao, Q., Chen, S., Lee, K. Y., Hsu, C. Y., & Xu, J. (2008). Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury. Journal of Neuroscience, 28(12), 3141-3149. https://doi.org/10.1523/JNEUROSCI.5547-07.2008

Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury. / Lee, Jin Moo; Yan, Ping; Xiao, Qingli; Chen, Shawei; Lee, Kuang Yung; Hsu, Chung Y.; Xu, Jan.

In: Journal of Neuroscience, Vol. 28, No. 12, 19.03.2008, p. 3141-3149.

Research output: Contribution to journalArticle

Lee, JM, Yan, P, Xiao, Q, Chen, S, Lee, KY, Hsu, CY & Xu, J 2008, 'Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury', Journal of Neuroscience, vol. 28, no. 12, pp. 3141-3149. https://doi.org/10.1523/JNEUROSCI.5547-07.2008
Lee, Jin Moo ; Yan, Ping ; Xiao, Qingli ; Chen, Shawei ; Lee, Kuang Yung ; Hsu, Chung Y. ; Xu, Jan. / Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury. In: Journal of Neuroscience. 2008 ; Vol. 28, No. 12. pp. 3141-3149.
@article{ff3657d915e646c9b7634ec0ac653dd6,
title = "Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury",
abstract = "Methylprednisolone (MP) is used to treat a variety of neurological disorders involving white matter injury, including multiple sclerosis, acute disseminated encephalomyelitis, and spinal cord injury (SCI). Although its mechanism of action has been attributed to antiinflammatory or antioxidant properties, we examined the possibility that MP may have direct neuroprotective activities. Neurons and oligodendrocytes treated with AMPA or staurosporine died within 24 h after treatment. MP attenuated oligodendrocyte death in a dose-dependent manner; however, neurons were not rescued by the same doses of MP. This protective effect was reversed by the glucocorticoid receptor (GR) antagonist (11, 17)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl) estra-4,9-dien-3-one (RU486) and small interfering RNA directed against GR, suggesting a receptor-dependent mechanism. MP reversed AMPA-induced decreases in the expression of anti-apoptotic Bcl-xL, caspase-3 activation, and DNA laddering, suggesting anti-apoptotic activity in oligodendrocytes. To examine whether MP demonstrated this selective protection in vivo, neuronal and oligodendrocyte survival was assessed in rats subjected to spinal cord injury (SCI); groups of rats were treated with or without MP in the presence or absence of RU486. Eight days after SCI, MP significantly increased oligodendrocytes (CC-1-immunoreactive cells) after SCI, but neuronal (neuronal-specific nuclear protein-immunoreactive cells) number remained unchanged; RU486 reversed this protective effect. MP also inhibited SCI induced decreases in Bcl-xL and caspase-3 activation. Consistent with these findings, the volume of demyelination, assessed by Luxol fast blue staining, was attenuated by MP and reversed by RU486. These results suggest that MP selectively inhibits oligodendrocyte but not neuronal cell death via a receptor-mediated action and may be a mechanism for its limited protective effect after SCI.",
keywords = "Apoptosis, Glucocorticoids, Methylprednisolone, Neurons, Oligodendrocytes, Spinal cord injury",
author = "Lee, {Jin Moo} and Ping Yan and Qingli Xiao and Shawei Chen and Lee, {Kuang Yung} and Hsu, {Chung Y.} and Jan Xu",
year = "2008",
month = "3",
day = "19",
doi = "10.1523/JNEUROSCI.5547-07.2008",
language = "English",
volume = "28",
pages = "3141--3149",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "12",

}

TY - JOUR

T1 - Methylprednisolone protects oligodendrocytes but not neurons after spinal cord injury

AU - Lee, Jin Moo

AU - Yan, Ping

AU - Xiao, Qingli

AU - Chen, Shawei

AU - Lee, Kuang Yung

AU - Hsu, Chung Y.

AU - Xu, Jan

PY - 2008/3/19

Y1 - 2008/3/19

N2 - Methylprednisolone (MP) is used to treat a variety of neurological disorders involving white matter injury, including multiple sclerosis, acute disseminated encephalomyelitis, and spinal cord injury (SCI). Although its mechanism of action has been attributed to antiinflammatory or antioxidant properties, we examined the possibility that MP may have direct neuroprotective activities. Neurons and oligodendrocytes treated with AMPA or staurosporine died within 24 h after treatment. MP attenuated oligodendrocyte death in a dose-dependent manner; however, neurons were not rescued by the same doses of MP. This protective effect was reversed by the glucocorticoid receptor (GR) antagonist (11, 17)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl) estra-4,9-dien-3-one (RU486) and small interfering RNA directed against GR, suggesting a receptor-dependent mechanism. MP reversed AMPA-induced decreases in the expression of anti-apoptotic Bcl-xL, caspase-3 activation, and DNA laddering, suggesting anti-apoptotic activity in oligodendrocytes. To examine whether MP demonstrated this selective protection in vivo, neuronal and oligodendrocyte survival was assessed in rats subjected to spinal cord injury (SCI); groups of rats were treated with or without MP in the presence or absence of RU486. Eight days after SCI, MP significantly increased oligodendrocytes (CC-1-immunoreactive cells) after SCI, but neuronal (neuronal-specific nuclear protein-immunoreactive cells) number remained unchanged; RU486 reversed this protective effect. MP also inhibited SCI induced decreases in Bcl-xL and caspase-3 activation. Consistent with these findings, the volume of demyelination, assessed by Luxol fast blue staining, was attenuated by MP and reversed by RU486. These results suggest that MP selectively inhibits oligodendrocyte but not neuronal cell death via a receptor-mediated action and may be a mechanism for its limited protective effect after SCI.

AB - Methylprednisolone (MP) is used to treat a variety of neurological disorders involving white matter injury, including multiple sclerosis, acute disseminated encephalomyelitis, and spinal cord injury (SCI). Although its mechanism of action has been attributed to antiinflammatory or antioxidant properties, we examined the possibility that MP may have direct neuroprotective activities. Neurons and oligodendrocytes treated with AMPA or staurosporine died within 24 h after treatment. MP attenuated oligodendrocyte death in a dose-dependent manner; however, neurons were not rescued by the same doses of MP. This protective effect was reversed by the glucocorticoid receptor (GR) antagonist (11, 17)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl) estra-4,9-dien-3-one (RU486) and small interfering RNA directed against GR, suggesting a receptor-dependent mechanism. MP reversed AMPA-induced decreases in the expression of anti-apoptotic Bcl-xL, caspase-3 activation, and DNA laddering, suggesting anti-apoptotic activity in oligodendrocytes. To examine whether MP demonstrated this selective protection in vivo, neuronal and oligodendrocyte survival was assessed in rats subjected to spinal cord injury (SCI); groups of rats were treated with or without MP in the presence or absence of RU486. Eight days after SCI, MP significantly increased oligodendrocytes (CC-1-immunoreactive cells) after SCI, but neuronal (neuronal-specific nuclear protein-immunoreactive cells) number remained unchanged; RU486 reversed this protective effect. MP also inhibited SCI induced decreases in Bcl-xL and caspase-3 activation. Consistent with these findings, the volume of demyelination, assessed by Luxol fast blue staining, was attenuated by MP and reversed by RU486. These results suggest that MP selectively inhibits oligodendrocyte but not neuronal cell death via a receptor-mediated action and may be a mechanism for its limited protective effect after SCI.

KW - Apoptosis

KW - Glucocorticoids

KW - Methylprednisolone

KW - Neurons

KW - Oligodendrocytes

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=41149117078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149117078&partnerID=8YFLogxK

U2 - 10.1523/JNEUROSCI.5547-07.2008

DO - 10.1523/JNEUROSCI.5547-07.2008

M3 - Article

C2 - 18354017

AN - SCOPUS:41149117078

VL - 28

SP - 3141

EP - 3149

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 12

ER -